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OBJECTIVE The objective of this review is to discuss the therapeutic use and differential treatment
response to Levo-carnitine (L-carnitine) treatment in septic shock, and to demonstrate common les-
sons learned that are important to the advancement of precision medicine approaches to sepsis. We
propose that significant interpatient variability in the metabolic response to L-carnitine and clinical
outcomes can be used to elucidate the mechanistic underpinnings that contribute to sepsis hetero-
geneity.
METHODS A narrative review was conducted that focused on explaining interpatient variability in L-car-
nitine treatment response. Relevant biological and patient-level characteristics considered include
genetic, metabolic, and morphomic phenotypes; potential drug interactions; and pharmacokinetics
(PKs).
MAIN RESULTS Despite promising results in a phase I study, a recent phase II clinical trial of L-carnitine
treatment in septic shock showed a nonsignificant reduction in mortality. However, L-carnitine treat-
ment induces significant interpatient variability in L-carnitine and acylcarnitine concentrations over
time. In particular, administration of L-carnitine induces a broad, dynamic range of serum concen-
trations and measured peak concentrations are associated with mortality. Applied systems pharma-
cology may explain variability in drug responsiveness by using patient characteristics to identify
pretreatment phenotypes most likely to derive benefit from L-carnitine. Moreover, provocation of
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S P E C I A L A R T I C L E
sepsis metabolism with L-carnitine offers a unique opportunity to identify metabolic response signa-
tures associated with patient outcomes. These approaches can unmask latent metabolic pathways
deranged in the sepsis syndrome and offer insight into the pathophysiology, progression, and
heterogeneity of the disease.
CONCLUSIONS The compiled evidence suggests there are several potential explanations for the variability
in carnitine concentrations and clinical response to L-carnitine in septic shock. These serve as
important confounders that should be considered in interpretation of L-carnitine clinical studies and
broadly holds lessons for future clinical trial design in sepsis. Consideration of these factors is
needed if precision medicine in sepsis is to be achieved.
KEY WORDS critical care, septic shock, pharmacometabolomics, systems pharmacology.
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Epidemiology and Heterogeneity of Sepsis
Sepsis is a life threatening, dysregulated host
response to infection, which is characterized by
systemic organ dysfunction.1 One in three Amer-
icans who die in the hospital have sepsis, and,
in 2017, there were an estimated 48.9 million
cases worldwide.2
The sepsis syndrome is highly heterogeneous,
with patients presenting along a continuum of
clinical signs, symptoms, and severity of illness.3
The mechanism and pathophysiology underlying
highly variable clinical trajectories in sepsis are
complex, and the precise reason(s) some
patients exhibit severe dysregulated responses
while others recover from their initial infection
in an uncomplicated fashion remains poorly
understood. Such host-response heterogeneity
muddies the interpretation of treatment response
and is a major reason why novel pharmacother-
apy often fails. Absence of adequate stratification
of patients based on their underlying pathophys-
iology may contribute to this.4 The need to
advance mechanistic understanding of sepsis
heterogeneity has led to calls from the National
Institute of General Medical Sciences for studies
that seek to determine the effect of patient char-
acteristics on differential treatment response
(NOT-GM-19-054). Teasing out this variability
is necessary to bring about a precision medicine
approach to sepsis.
Ample evidence suggests a hypermetabolic
component and derangement of host metabolism
that is central to sepsis pathophysiology.5
Recently revised consensus guidelines define the
most severe manifestation, septic shock, as infec-
tion with sustained hypotension despite recom-
mended evidence-based treatment interventions
(e.g., fluid resuscitation), and pertinent to this
discussion, metabolic dysfunction and/or tissue
hypoperfusion as evidenced by an elevated blood
lactate concentration.1 Hyperglycemia, protein
catabolism, and lipolysis are similarly known to
occur in sepsis and contribute to poor patient
outcomes.6 Although several studies have tar-
geted lactate as a resuscitation goal,7–9 these tri-
als have typically utilized fluids, vasopressors, or
other agents designed to improve organ perfu-
sion under the assumption that lactate elevations
are predominantly explained by ongoing tissue
ischemia, which may not necessarily be true.10
Current pharmacotherapy neither targets nor
corrects these metabolic perturbations, although
restoration of host bioenergetics offers a promis-
ing therapeutic target. Moreover, given the
prevalence, persistent mortality, and lack of
specific treatment paradigms, there is a critical
need to advance understanding of the range and
extent of the metabolic consequences of sepsis
beyond observational studies.
Herein, we discuss clinical trials of L-carnitine,
an important regulator of mitochondrial and
metabolic homeostasis, for the treatment of sep-
tic shock. We consider how patient-level biologi-
cal variables impact response to treatment and
propose that provocation with L-carnitine offers
a novel and unique opportunity to improve
mechanistic understanding of the heterogeneity
and metabolic consequences of sepsis.
Physiological Role of Carnitine and Treatment
in Sepsis Patients
Carnitine is an endogenous, polar small-mole-
cule derived from lysine and methionine, which
plays a well-established, crucial role in transport
of long-chain fatty acids into the mitochondria
for b-oxidation. Other key roles during times of
metabolic stress include maintenance of coen-
zyme A homeostasis, metabolic flexibility, and
promotion of normal tricarboxylic acid cycle
(TCA cycle) function, and further oxidation of
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fatty acids by peroxisomes.11 A full, in-depth
review of carnitine and acylcarnitine homeostasis
and biochemistry is outside the scope of this
paper, and it has been extensively reviewed else-
where.11, 12 Briefly, the carnitine shuttle allows
for fatty acid entrance to the mitochondria for
oxidation and subsequent energy production
through transfer of acyl groups and conversion
into acylcarnitines (Figure 1).
In sepsis, mitochondrial dysfunction has been
increasingly reported as a critical factor in per-
sistent organ failure and altered peripheral cell
mitochondrial function is known to be associ-
ated with sepsis mortality.14,15 Further evidence
of mitochondrial dysfunction includes elevations
of systemic acylcarnitines, indicating incomplete
b-oxidation of fatty acids, and the presence of
mitochondrial deoxyribonucleic acid (DNA) in
plasma.16,17 Sepsis alterations in mitochondrial
function and lipid metabolism are associated
with kidney and liver function that are driven in
part through inhibition of the pyruvate dehydro-
genase complex and decreased activity of car-
nitine palmitoyltransferase I.18,19 Prior clinical
studies of i.v. L-carnitine and acetylcarnitine
given to patients in cardiogenic and circulatory
shock found an overall positive effect on hemo-
dynamic parameters and patient survival.20–22
These principles served as the basis for two
recent clinical trials of L-carnitine in septic
shock. The first was a phase I, randomized, dou-
ble-blind clinical trial of L-carnitine (12 g i.v.)
Figure 1. Overview of carnitine transport and enzymatic conversions in the cell. Carnitine enters the cell from the blood
through an organic cation transporter (OCTN2), after which carnitine palmitoyl transferase I (CPT-1) facilitates the
conversion of carnitine and long-chain fatty acid-coenzyme As (CoAs) to acylcarnitines and CoA. The transporter carnitine-
acylcarnitine translocase (CACT) moves the newly formed long-chain acylcarnitines into the mitochondrial matrix in
exchange for free carnitine. Here, long-chain acyl groups are transferred back to CoA by carnitine palmitoyl transferase II
(CPT-II). The newly regenerated acyl-CoA undergoes b-oxidation into Acetyl-CoA, which feeds into the tricarboxylic acid
cycle (TCA) cycle. Alternatively, carnitine acetyl-transferase (CAT) converts free carnitine and acetyl-CoA to acetylcarnitine,
which can freely diffuse through CACT and OCTN2 back into the bloodstream. This latter process may be enhanced during
sepsis and times of metabolic stress, serving as a crucial sink for excess acetyl groups that may be toxic to the cell. The
ladder cartoon represents the plasma membrane separating the blood and the cytosol of the cell, whereas grey boxes
represent the outer and inner membranes of the mitochondria. (Open-source through the Creative Commons Attribution,
obtained with permission from https://doi.org/10.1016/j.ebiom.2017.01.026.)13 [Color figure can be viewed at wileyonlinelib
rary.com]
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versus saline placebo conducted in 31 patients
with septic shock enrolled within 16 hours of
diagnosis.23 Study drug was given as an i.v.
bolus (33% of total dose), followed by a 12-hour
infusion that delivered the remaining drug. This
study found no difference in the reduction of
Sequential Organ Failure Assessment (SOFA)
score at 24 hours, but there was an improve-
ment in mortality at 28 days (4/16 vs 9/15,
p=0.048) and 1-year (8/16 vs 12/15, p=0.081) in
L-carnitine treated patients. Adverse events
sometimes attributable to L-carnitine, including
gastrointestinal distress, body odor, and an
decreased seizure threshold, were not observed
in the study. In addition, serious adverse events
were not significantly different between the L-
carnitine and placebo treatment arms. A follow-
up phase II multicenter, double-blind, adaptive
dose-finding trial randomized 250 patients
within 24 hours of identified septic shock to i.v.
L-carnitine (6, 12, or 18 g) versus placebo.24 In
the primary analysis, the highest dose (18 g) of
L-carnitine was not found to be superior to pla-
cebo in reducing the total SOFA score at 48
hours, and the predicted probability of success
of a subsequent phase III trial in reducing mor-
tality at 28 days did not exceed the a priori
threshold of 90%. The 6 and 12 g L-carnitine
doses underperformed in the trial and were
adaptively dropped from the randomization
scheme as the trial progressed. Three, interim,
preplanned safety and futility analyses were
completed by an independent data safety moni-
toring board.
However, the primary end points of both clin-
ical studies do not describe a critical component
of drug response to supplemental L-carnitine in
patients with septic shock. The pharma-
cometabolomics data from the phase I trial
reveal substantial interpatient variability in
serum carnitine and acetylcarnitine concentra-
tions postinfusion.25,26 Patients receiving L-car-
nitine in the phase I study had 24-hour
postinfusion (T24) serum carnitine levels rang-
ing from 30 µM to over 1600 µM (median =
368 µM). The temporal changes in carnitine and
acetylcarnitine for the treatment and placebo
arms are shown in Figure 2. Critically, L-car-
nitine treated nonsurvivors (based on 1-year
mortality) had elevated carnitine and acetylcar-
nitine (C2), short chain acylcarnitines (C3, C4,
and C5), and long chain acylcarnitines (C14 and
C16) compared with L-carnitine treated sur-
vivors. This suggests the observed variability in
measured peak concentrations and metabolic
response profiles are associated with clinical out-
comes. As such, identification of the patient-
level factors associated with peak carnitine/acyl-
carnitine concentrations may help identify
patients most likely to derive a mortality benefit
from L-carnitine and inform the design of future
clinical studies.
Candidate Mechanisms of Interpatient
Variability of Drug Response in Sepsis
Pharmacogenomics
Pharmacogenomics seeks to explain variability
in drug exposure and response based on genetic
differences between individuals. Genetic varia-
tion in drug metabolizing enzymes, transporters,
and targets impact an individual’s exposure and/
or response to a given pharmacologic therapy,
which can manifest as distinct drug-response
phenotypes. Genetic variability is also known to
alter patient response across disease states and
medications commonly seen in the intensive
care unit (ICU).28 Treatment and dosing para-
digms, which incorporate patient-specific phar-
macogenomic data, hold promise in decreasing
adverse drug events (ADEs) and improving effi-
cacy.29 Moreover, rationale clinical trial enroll-
ment based on pharmacogenomic phenotypes
can foster a more homogenous patient cohort
and target patient populations most likely to
benefit from therapy (Table 1).
Genetic variability in a number of enzymes
and transporters could contribute to L-carnitine
drug response, including those highlighted in
the carnitine shuttle (Figure 1). Carnitine acts
intracellularly and is highly sequestered in skele-
tal muscle and other tissues of the body.11 Given
the polar structure of carnitine, active sodium-
dependent transport by organic cation/carnitine
transporters (OCTNs) is required for entry from
the blood into the cell and subsequent facilita-
tion of fatty acid b-oxidation. The primary car-
nitine transporter, OCTN2, thus represents the
focus of this section.
The OCTN2 transporter is encoded by the
SLC22A5 gene located on chromosome 5q31.1.
Spanning 25 kb, the 10 exons of this gene encode
the full length 557 amino acid protein. Numerous
autosomal recessive mutations in the SLC22A5
gene are responsible for primary carnitine defi-
ciency and results in low serum carnitine levels
due to the kidney’s impaired ability to reabsorb
the molecule.30 Missense mutations are exceed-
ingly rare, result in severe metabolic and
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mitochondrial dysfunction, and manifest clini-
cally as a primary carnitine deficiency at a young
age. As such, loss of function mutations are unli-
kely to play a role in explaining variability in L-
carnitine concentrations or response in clinical
studies of adults with septic shock. Nonetheless,
given the vital role of OCTN2 in carnitine uptake
into the cell, and considering the large doses
administered in these trials, more common
genetic polymorphisms in OCTN2 resulting in
reduced function and / or expression may
improve understanding of the mechanisms that
explain the broad dynamic range of carnitine con-
centrations after supplementation.
Common polymorphisms (i.e., minor allele
frequency greater than 1%) in the OCTN2 gene
and their impact on carnitine transport outside
the context of primary carnitine deficiency are
rare.31–33 Three single-nucleotide polymor-
phisms (SNPs; Phe17Leu, Tyr449Asp, and
Val481Asp) were associated with reduced
OCTN2 function compared with wild-type, and
a SNP in the promoter region of the gene
(207C>G) was associated with increased car-
nitine transport capacity and trended toward
increase mRNA expression in cell lines.31 Out of
these, only the promoter region variant
(207C>G, rs2631367) could be considered
common according to the National Center for
Biotechnology Information database of genetic
variation (database [db]SNP).34 Further studies
have observed a tissue-specificity to the
207C>G variant’s effect on mRNA expression
levels.32,33
Figure 2. Carnitine treatment induces a metabolic phenotype whereby serum carnitine and acetylcarnitine concentrations are
elevated in sepsis nonsurvivors. Serum concentrations of carnitine and acetylcarnitine are plotted over time for patients
treated with either L-carnitine (panels A and C) or saline placebo (panels B and D). Data plotted are the median, 25th, and
75th percentile of observed serum concentrations, and the Mann–Whitney U test was used to determine significant
differences between non-survivors and survivors at each timepoint. All p values are corrected for multiple comparison using
a false discovery rate method according to Storey and colleagues27 and are reported as q values. L-carnitine treated
nonsurvivors (N=7–8) at 1-year had significantly higher concentrations of carnitine relative to survivors (N=8) at baseline
(BL, q = 0.02); 24-hours (T24, q = 0.004); and 48-hours (T48, q = 0.02) posttreatment. Similar trends were observed for
acetylcarnitine (BL, q = 0.01; T24, q = 0.003; and T48, q = 0.02). No significant differences in carnitine or acetylcarnitine
concentrations were observed between placebo treated non-survivors (N=8–12) and survivors (n=3).
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To supplement the limited literature regarding
common polymorphisms effecting OCTN2, we
conducted a systematic bioinformatics search for
potentially relevant SNPs. We queried the Geno-
type-Tissue Expression (GTEx) Project (avail-
able at https://gtexportal.org/home/), which
seeks to explain variability in mRNA expression
levels from previously healthy human cadavers
with whole genome sequencing.35 The goal of
this query was to determine common genetic
variants (i.e., SNPs) that significantly alter gene
expression of the OCTN2 transporter. Using
expression quantitative trait loci (eQTL) analy-
sis, ~1500 variants were found to be associated
with altered gene expression at the tissue level.
Summing across more than 6000 SNP/tissue
pairs, the variant with the largest effect on net
OCTN2 gene expression was the promoter
region variant (207C>G, rs2631367).
In previously unpublished data from our
group, patients treated with L-carnitine in the
phase I trial23 were genotyped for the OCTN2
(207C>G) SNP. In this preliminary study, 14
patients had both genomic and serum carnitine
concentrations measured at 24 hours (T24).
Among these, 4 patients were wild-type (CC),
whereas 10 carried 1 or 2 copies of the G allele.
Patients with the C/G or G/G genotype trended
toward lower T24 plasma levels of L-carnitine
(p=0.11), suggesting that genetic variation in the
OCTN2 transporter may contribute to variability
and persistent elevations in L-carnitine after sup-
plementation during septic shock. More pharma-
cogenetic studies are needed and are underway
in the phase II trial24 to determine if variation in
OCTN2 and other carnitine-specific enzymes
and / or transporters explain interpatient vari-
ability in L-carnitine drug response.
Drug Interactions
Drug interactions occur when the activity,
exposure, or effectiveness of a drug is impacted
by the presence of another drug. Co-adminis-
tered drugs may inhibit or induce expression of
important enzymes or transporters, compete at
target binding sites, or act in a synergistic or
antagonistic fashion. Different combinations of
drugs and their interactions introduce variability
in the pharmacokinetic (PK) and pharmacody-
namic (PD) response to pharmacologic therapy,
which may put patients at increased risk of
ADEs and either mitigate or enhance therapeutic
efficacy. Critically ill patients are at increased
risk of drug interactions and subsequent compli-
cations given comorbidities and disease compli-
cations that are often present (e.g., renal failure)
and the requisite complex treatments regimens
prescribed.36,37 In other disease states, such as
cancer, there is a high prevalence of drug inter-
actions in patients enrolled in clinical trials.38
Drug interactions in critically ill patients may
pose a similar threat to trial validity and patient
health and should be systematically screened
and considered (Table 1).
For L-carnitine, several drugs are reported to
inhibit the OCTN2 transporter and, therefore,
could contribute to interpatient variability in




drug response in sepsis
Impact on L-carnitine trial design and
interpretation
Influence on improving precision medicine
in sepsis
Pharmacogenomics Genetic variance in the transport receptor of
L-carnitine (OCTN2) may influence drug
concentration at site of action
Stratify patients by genotype at the time
clinical trial enrollment
Drug interactions Co-administration of OCTN2 inhibitors,
including commonly used antibiotics, and
vasopressors, may influence drug
concentrations
Thorough screening for potential drug
interactions by clinical pharmacists at time
of trial enrollment and post hoc
Pharmacometabolomics Baseline and dynamic metabolic signatures are
associated with elevated drug concentrations
and patient mortality
Target metabolic subgroups for trial
enrollment and measure metabolic response
signatures post drug administration
Morphomics Patient muscle mass and body composition
may influence metabolic adaptability,
energetic stores, and drug distribution
Consider variation in body size and
composition when testing targeted
metabolic therapeutics
Renal function and PKs Altered renal clearance and reabsorption of
drug and acyl-metabolites may influence
drug concentrations and patient outcomes
Embedded clinical pharmacology studies to
quantify sepsis pathophysiology induced
alterations in drug PK
OCTN2 = organic cation/carnitine transporter; PK = pharmacokinetic.
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exposure. These drugs can also cause secondary
carnitine deficiency through inhibition of the
OCTN2 transporter in the kidneys leading to
decreased efficiency of reabsorption.39 Of partic-
ular interest, in the setting of sepsis, are two
widely used classes of medications, namely
antibiotics and vasopressors. Previous reports
have demonstrated that cefepime and levofloxa-
cin inhibit OCTN2 in vitro.40,41 Although the
choice of antibiotic therapy in sepsis depends on
a number of patient-specific factors, cefepime
and levofloxacin are two commonly used antibi-
otics in the United States and are both recom-
mended options in evidence-based best
practices. Vasopressors, such as norepinephrine
and other catecholamines, used to maintain
blood pressure support, and other commonly
used medications, including omeprazole and val-
proic acid, inhibit OCTN2 and could similarly
impact L-carnitine drug response.39 In addition
to omeprazole, other proton-pump inhibitors,
including pantoprazole and lansoprazole, have
been shown to inhibit similar organic ion trans-
porters but whether they interfere with the func-
tion of OCTN2 and carnitine transport has not
been reported.42
Propofol, a short-acting hypnotic and sedative
that is widely used in the ICU, may also play a
critical role in understanding variable drug
response to L-carnitine. Propofol is known to
inhibit carnitine palmitoyltransferase I and the
mitochondrial electron transport chain, which
leads to incomplete b-oxidation of fatty acids.43
The induced metabolic disruptions have been
linked to propofol infusion syndrome (PRIS), a
severe adverse effect of propofol that includes
bradycardia, arrhythmias, rhabdomyolysis, meta-
bolic acidosis, hepatomegaly, hyperlipidemia,
and organ failure. Moreover, animal and in vitro
experiments have suggested a role for L-carnitine
and acetylcarnitine in restoring propofol inhibi-
tion of fatty acid metabolism.44,45
Variable exposure to one or more of these
drugs could influence resulting blood concentra-
tions and subsequent metabolic response to sup-
plemental L-carnitine. Other mechanisms are
certainly possible such that other concomitant
medications and variable patient feeding may
further confound the clinical studies discussed
above. Presently, the clinical relevance of such
interactions and how they should be managed is
currently unknown. Further investigation into
the use of these drug inhibitors and the effect
on L-carnitine concentrations in the phase II
study is underway.
Pharmacometabolomics
Metabolomics seeks to identify and quantify
small molecules, the full collection of which
define the metabolome, in a given biofluid.46
The metabolome constitutes a read-out of under-
lying cellular and biochemical events that reflect
the genetic makeup of the host, transcriptomic,
and proteomic influence, as well as variability in
the microbiome and environmental exposure. As
such, metabolomics represents the culmination
of these important regulators on the host. In
addition, given that metabolism is dynamic on a
practical and physiological time scale, this
sensitivity can inform heterogeneity in disease
trajectory and treatment response. Pharma-
cometabolomics exploits this paradigm and is
aimed at understanding and predicting response
to drug treatment. In short, clinical application
of metabolomics holds great promise in improv-
ing the diagnosis and risk stratification of criti-
cally ill patients, furthering drug discovery
through metabolic signatures of drug response
and/or ADEs, and elucidating biochemical path-
ways involved in the pathophysiology of critical
illness (Table 1).
A pharmacometabolomic approach was uti-
lized to understand baseline metabolic differ-
ences in patients treated in the phase I study of
L-carnitine.26 Patients treated with L-carnitine
who had low baseline levels of the ketone levels,
3-hydroxybutyrate, also had lower posttreatment
carnitine levels at 24 hours. The L-carnitine trea-
ted, low-ketone patients also had better clinical
outcomes as evidenced by a timelier reduction
in vasopressor requirement and decreased 1-year
mortality. An untargeted metabolomics approach
was then conducted in male patients from the
phase I study.47 The L-carnitine treated non-sur-
vivors were found to have posttreatment eleva-
tions in metabolites related to vascular
inflammation, including histamine, allysine, and
fibrinopeptide A. Along with the differential
metabolic response of survivors and nonsur-
vivors highlighted in Figure 2, these data suggest
both baseline metabolic signatures and metabolic
profiles over time may be predictive of L-car-
nitine treatment responsiveness.
Morphomics
Analytic morphomics is a new and rapidly grow-
ing scientific discipline within precision pharma-
cotherapy that studies how variation in body size,
composition, and structure are associated with drug
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and disease response.48 In sepsis, two recent meta-
analyses have observed a paradox between body
composition and survival, whereby particularly
overweight (body mass index [BMI] between 25
and 29.9 kg/m2), and to a lesser extent obese (BMI
between 30 and 40 kg/m2), patients tend to have
better mortality outcomes compared with normal
weight individuals (BMI between 18.5 kg/m2 and
24.9 kg/m2).49,50 Notably, underweight (BMI less
than 18.5 kg/m2) and morbidly obese (BMI greater
than 40 kg/m2) patients were found to have similar
risk of mortality relative to normal weight individu-
als. Neither measured peak concentrations of L-car-
nitine nor mortality were significantly associated
with BMI in patients who received study drug in
the phase I study. However, the observed “obesity
paradox” reinforces the concept of a metabolic and
energy-driven component to sepsis pathophysiol-
ogy and has a number of possible pathophysiologi-
cal explanations, including increased energy stores,
antiinflammatory mediator release from adipose tis-
sue, and lipoprotein binding of bacterial cellular
components.51
Another possible explanation is that increased
muscle mass offers energetic and metabolic
adaptability to patients within a window of the
BMI spectrum. Protein catabolism and subse-
quent myopathy are observed in critically ill
patients, and skeletal muscle, an important ener-
getic source to the host, experiences mitochon-
drial injury over the course of sepsis.52 Indeed,
recent studies have found an association
between low muscle mass and increased risk of
mortality for patients with sepsis. In 74 patients
with liver cirrhosis and sepsis, patients with low
muscle mass (defined as mid-arm muscle cir-
cumference lower than the fifth percentile of the
population) had increased mortality compared
with patients with normal muscle mass (47%
compared with 26%, p=0.06).53 In a separate
retrospective review of 627 patients with a diag-
nosis of sepsis and an available abdominal com-
puted tomography scan of the psoas muscle,
muscle mass depletion was associated with 28-
day mortality in both univariate and multivariate
logistic regression (odds ratio [OR] = 2.79,
p=0.01).54 Given the extent of protein catabo-
lism, the sepsis-obesity paradox, and the known
sequestering of carnitine into muscle tissue,
morphomics and variability in body composition
offers a currently untapped field that could aid
in explaining the observed variability in
response to supplemental L-carnitine and patient
mortality in sepsis broadly (Table 1).
Pharmacokinetics and Renal Function
Pharmacokinetics (PKs) as a science seeks to
understand what the body does with and to
drugs. More specifically, it is the study of how
drugs are absorbed, distributed, metabolized,
and eliminated from the body. Previous studies
have highlighted that there is profound sepsis-
induced variation in drug PKs. The reasons for
this are likely multifaceted but include altered
protein binding, perturbed vascular and tissue
permeability, decreased hepatic and renal blood
flow, and lower activity of drug metabolizing
enzymes.55 High interpatient variability in drug
PK in sepsis clinical trials contributes to overall
heterogeneity of the patient cohort and may con-
found trial results unless careful analysis of drug
exposure is considered (Table 1).
The PKs of L-carnitine has been explored;
however, no studies have determined the precise
PKs of L-carnitine in sepsis or at such high intra-
venous doses. As discussed above, OCTN2 is a
critical carnitine transporter that is responsible
for carnitine uptake into cells/tissues, however,
it is also responsible for reabsorption of car-
nitine in the kidney proximal tubule. As such,
kidney function may play a vital role in the
interpatient variability in serum carnitine con-
centrations that result after supplementation.
Previous reviews report an average renal clear-
ance of endogenous carnitine of 1 to 3 ml/min,
indicating that at physiologically relevant con-
centrations up to 99% of carnitine is reabsorbed
by the kidneys.56 Exogenous carnitine adminis-
tered to healthy volunteers, increased renal
clearance of carnitine and acetylcarnitine, indi-
cating saturation of the OCTN2 transporter and
the reabsorption process, may be relevant for
supraphysiologic doses of intravenous carnitine
like those given in septic shock trials.56 Unfortu-
nately, urine samples were not collected in these
studies, which prevents us from estimating renal
clearance of relevant carnitine species in these
patients. Both studies reported similar serum
creatinine levels among survivors and nonsur-
vivors indicating renal function alone does not
explain heterogeneity in L-carnitine and acylcar-
nitine concentrations among patients. However,
the reliability of creatinine as a biomarker in the
setting of acute kidney injury (AKI), sepsis, and
other critical illnesses, and in drug development
broadly have been called into question.57,58 New
investigations of biomarkers of kidney injury
and function are underway, but have yet to be
widely adapted or clinically validated. Further
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investigations of the variability in L-carnitine
drug response stratified by the presence of AKI
and acute liver injury, and among other mea-
sures of organ dysfunction are warranted before
precise clinical recommendation can be made in
these patient groups. Moreover, modeling the
impact of patient-level biological variables, such
as sex, age, and race, is critical to understand
the observed heterogeneity in L-carnitine drug
response.
Metabolic Provocation with Supplemental L-
carnitine
Although the approaches outlined above offer
an opportunity to identify patients with sepsis
most likely to respond to L-carnitine, under-
standing the metabolic response signature of L-
carnitine treated patients holds value beyond a
potential therapeutic benefit. Outside of sepsis,
the concept of provoked metabolic testing is
used to uncover latent disease phenotypes. For
example, a glucose tolerance test is used to
diagnosis a previously undetectable pre-diabetic
phenotype in pregnant women. As seen in Fig-
ure 2, the metabolic response profiles of the
placebo arm did not differentiate patient mor-
tality at 1-year, as they did for L-carnitine trea-
ted patients. Critically, this finding suggests the
possibility that treatment with L-carnitine
amplifies or incites a phenotype of sepsis mor-
tality and underlying derangement in carnitine
homeostasis. Indeed, elevations in plasma acyl-
carnitines are understood to be a measure of
mitochondrial dysfunction and altered coen-
zyme A homeostasis in other metabolic diseases
and elevated acetylcarnitine were recently found
to be predictive of plasma cytokine levels,
blood culture positivity, multiorgan dysfunc-
tion, and mortality in patients with sepsis.59
Others have shown that short chain acylcarniti-
nes levels are related to plasma mitochondrial
DNA, an indicator of cellular damage, and that
acylcarnitines are predictive of mortality in crit-
ically ill patients.16,17 Together, these data sug-
gest derangements of the carnitine/acylcarnitine
pool may be indicative of metabolic dysfunction
and/or worsening sepsis that is predictive of
mortality.
A metabolic test with supplemental L-carnitine
can provoke biochemical pathways in sepsis and
amplify signals of underlying mitochondrial dys-
function and perturbed energy pathways. A
more complete investigation of other metabolite
profiles that are disrupted upon treatment may
also lead to new insights into underlying disease
mechanism and pathophysiology. Although there
are a number of sepsis metabolomics studies that
confirm the substantial metabolic disturbances
of the disease, they do not inform distinct sepsis
phenotypes in the way that a metabolic provoca-
tion test could. The substantial variability in
response to L-carnitine exposure and subsequent
mortality differences indicate phenotypic differ-
ences between groups. In aggregate, this obser-
vation introduces the principle that even in the
presence of a disease like sepsis, which is known
to induce a substantial metabolic perturbation,
provocation of metabolism is required to bring
the full dynamic range into view.
Conclusion and Future Directions
L-carnitine and acylcarnitine concentrations
are highly variable after L-carnitine supplemen-
tation in septic shock, and the observed inter-
patient variability is associated with patient
mortality. The heterogeneity of sepsis and drug
response complicates the interpretation of a
therapeutic value of L-carnitine and other
potential sepsis pharmacotherapies. Currently,
a careful analysis of the phase II clinical trial
to inform the design of, and the results from,
a phase III trial are needed before L-carnitine
treatment can be recommended for a specific
sepsis patient population. However, even
though more work needs to be done, a strat-
egy using the patient-level factors and biologi-
cal variables that impact L-carnitine drug
response could be used in the a priori identifi-
cation of patients who are most likely to
derive the greatest benefit from treatment.
Well defined phenotypes of drug response
could serve as inclusion-exclusion criteria and
aid in the design and interpretation of future
phase III clinical studies of L-carnitine. Such
information will need to be balanced with
threats to clinical and external validity, as well
as consideration to the ability to recruit a suf-
ficient patient population.
The approach outlined here is applicable to
other emerging sepsis therapeutics and could aid
in developing a precision medicine approach to
sepsis and the design of early-phase clinical tri-
als in critical illness. Moreover, provoking meta-
bolism in septic shock with L-carnitine
supplementation offers a unique opportunity to
define metabolic signatures of survival and eluci-
date biochemical pathways deranged in the sep-
sis syndrome. Such an approach offers a novel
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mechanism to further the understanding of sep-
sis pathophysiology and progression, as well as
elucidate drug response phenotypes.
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